Click on a filter below to refine your search. Remove a filter to broaden your search.
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Although significant associations are seen for both, the associations are more pronounced in women.
The findings were seen for both all-cause and cardiovascular death.
Proportionately lower log odds were seen for heart disease, heart attack, stroke and composite outcome for days of use between zero and 30 a month.
Regular physical activity was linked to a reduced risk for all-cause mortality in women and men, with a greater reduction for women.
The agency estimates that the new standard will prevent up to 4,500 premature deaths in the first year of full enforcement.
No similar benefit was seen for resistance exercise alone in adults with overweight or obesity, however.
Death rates from cardiovascular disease have fluctuated over the years and trended upward recently.
The increase in risk ranges from 16 to 34% for all-cause and cardiovascular disease mortality.
Some of the factors include social isolation, diabetes, heart disease, vitamin D deficiency, high C-reactive protein and low handgrip strength.